PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2026Cancer Immunology Research0 citations

Abstract B038: Inflammatory spatial niches distinguished by antigen presentation and interferon response programs explain the high immune response rate of desmoplastic melanoma: Comparison of biopsies from SWOG S1512 and S1616

View Full Paper
DCDaniel ChenATAmanda TruongNDNataly Naser Al Deen

Key Points

  • This research aims to investigate the unique tumor microenvironment characteristics of desmoplastic melanoma contributing to enhanced immune responses.
  • Conducted spatial transcriptomics on melanoma biopsies from two clinical trials.
  • Analyzed pre- and post-treatment samples from both desmoplastic and non-desmoplastic melanoma patients.
  • Performed differential gene expression analysis and spatial neighborhood composition analysis.
  • Desmoplastic melanoma tumor cells exhibited higher expression of immune-attracting chemokines CCL19 and CCL21.
  • Non-desmoplastic melanoma cells showed elevated levels of the Treg-associated chemokine CCL28.
  • Spatial analyses indicated that desmoplastic tumors are closely associated with fibroblasts and vascular endothelial cells, enhancing immune cell recruitment.

Abstract

Abstract Background: Immune checkpoint blockade (ICB) has revolutionized cancer treatment by inducing remission in patients who were refractory to traditional therapies. By removing the brakes from anti-tumor immune cells, ICB has led to remarkable responses in several cancer types. However, these responses are not homogenous. Within cutaneous melanomas, desmoplastic melanomas (DMs) present with markedly better responses to ICB; a recent phase II trial (SWOG S1512, NCT02775851) with pembrolizumab (anti-PD1) demonstrated an overall response rate of 89%. These findings contrast with prior work in “cold” tumors, such as pancreatic ductal adenocarcinoma, where prominent desmoplasia has been found to inhibit the anti-tumor immune response. This difference brings us to question the intrinsic (tumor cell) and extrinsic (microenvironment) derived signals that position DM tumor microenvironments (TMEs) to respond this positively to ICB. Methods: We performed spatial transcriptomics on biopsies from patients with DM (n=7 pre and n=14 post -treatment from S1512) and non-desmoplastic melanomas (non-DM, n=15 pre and n=14 post -treatment from S1616) using NanoString CosMx (1,000-plex). We collected 2,661,379 high-quality spatially-resolved single cell transcriptomes with readily identifiable tumor, stroma, and immune cell populations. We performed differential gene expression analysis via pseudo-bulking of in silico isolated cell populations with gene set enrichment analysis. Spatial analyses consisted of the identification of differential neighborhood composition (cell type) and function (expressed genes and pathways) between DM and non-DM TMEs. Results: DM tumor cells and associated stroma, fibroblasts, were found to differentially express potent immune cell attractants such as CCL19 and CCL21, known to recruit T and dendritic cells. In contrast, non-DM tumor cells markedly upregulated Treg associated chemokine, CCL28. Spatial analyses revealed DM tumor cells to not only be physically proximal to fibroblasts, consistent with histopathology, but also to vascular endothelial cells that may facilitate immune cell recruitment into DM tumors. DM TMEs were further distinguished through tumor cell spatial neighborhoods differentially enriched for antigen presentation and interferon response pathways. In line with the inflammatory nature of these neighborhoods in DM TMEs and increased expression of chemokines by DM tumor cells, we also found these niches to be rich with lymphocytes (B and T cells) and myeloid cells that are likely the agents poised to enact the efficacious anti-tumor response observed in patients with DM treated with ICB. Conclusion: In all, through spatially-resolved transcriptomics, we found DM tumors to possess uniquely inflammatory spatial niches that may facilitate a more positive response to ICB through prevalent local vasculature to mediate immune cell infiltration into the TME and coordinated upregulation of antigen presentation machinery in an interferon response associated manner to allow for immune cell recognition and thus cancer clearance. Citation Format: Daniel G. Chen, Amanda Truong, Nataly Naser Al Deen, Cynthia R. Gonzalez, Ignacio Baselga-Carretero, Jia M. Chen, Kari L. Kendra, Zeynep Eroglu, Siwen Hu-Lieskovan, Ari M. Vanderwalde, David A. Wada, Jose A. Plaza, Michael C. Wu, Philip O. Scumpia, Antoni Ribas, Katie M. Campbell. Inflammatory spatial niches distinguished by antigen presentation and interferon response programs explain the high immune response rate of desmoplastic melanoma: Comparison of biopsies from SWOG S1512 and S1616 abstract. In: Proceedings of the AACR Immuno-Oncology Conference (AACR IO): Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2026 Feb 18-21; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2026;14(2 Suppl):Abstract nr B038.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69994cd2873532290d0219f7https://doi.org/10.1158/2326-6074.io2026-b038
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 6564: Spatially resolved immunologic hallmarks of response to neoadjuvant immune checkpoint blockade in metastatic melanoma2026
  2. 2Abstract A036: Spatial multi-omics identifies a tumor microenvironment signature predictive of immunotherapy response in mucosal melanomas2026
  3. 3Abstract 2486: Dissecting tumor-immune interaction in response and resistance to immune checkpoint blockade in metastatic melanoma2024
  4. 4Abstract 7750: Integration of spatial single cell proteomics and spatial metabolomics reveals tumor microenvironment predictive of immunotherapy response in mucosal melanoma2026
  5. 5Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma2024 · 15 citations